Delivery Order SPE2DB24D1205-SPE2DB25FCZND
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,474.93 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 15, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and inflammatory conditions, including...
- The Defense Logistics Agency awarded a $59,468.29 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This non-set-aside competitive award is scheduled for completion by August 28, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis and other inflammatory conditions, representing a...
- The Defense Logistics Agency awarded a $27,552.50 delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of June 6, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily indicated for moderate-to-severe atopic dermatitis, eosinophilic...
- The Defense Logistics Agency awarded a $40,995.34 delivery order to AmerisourceBergen Drug Corp on April 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, non-set-aside contract specifies firm fixed pricing with an ultimate completion date of April 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors with a firm fixed price of $3,418.92 and an ultimate completion date of August 15, 2025. This non-set-aside award was issued on August 14, 2025, with performance to be completed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic asthma, and chronic...
- The Defense Logistics Agency awarded a $56,394.80 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's distribution...
- The Defense Logistics Agency awarded a $13,630.99 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,418.92 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 8, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to...
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZNDDelivery Order
The Defense Logistics Agency awarded a $26,328.21 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and asthma, representing a specialized pharmaceutical need within the federal healthcare supply chain. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of brand-name and generic medications, vaccines, and medical devices to support military and veteran healthcare systems worldwide. The company's competitive selection for this specialized pharmaceutical delivery reflects its capability to fulfill federal medical supply requirements across multiple therapeutic domains through the DLA's global pharmaceutical support program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.3k | 8/13/25 |